Table 1.
Baseline Characteristics
| IV-20 Arm | PO-35 Arm | Control Arm | |
|---|---|---|---|
| N randomized | 20 | 20 | 21 |
| Age, median (IQR) years | 33.5 (25.5–38.5) | 32.5 (26.5–38.5) | 34.0 (27– 36) |
| Gender, male N (%) | 13.0 (65) | 12.0 (60) | 9.00 (42.9) |
| Weight, median (IQR), kg | 55 (47.5–58.5) | 50.5 (50–55) | 50.0 (45–55) |
| HIV details | |||
| HIV-positive, N (%) | 18.0 (90) | 18 (90) | 20 (95.2) |
| HIV-negative, N (%) | 2 (10) | 2 (10) | 1 (4.80) |
| Amongst those HIV positive: | |||
| CD4 T-cell count, cells/µL | 55 (45–59) | 50.5 (50–55) | 50 (45–55) |
| HIV viral load, median (IQR) copies/mL | 7840 (4014 – 574 462) | 6523 (4815 – 92 346) | 2334 (945 – 19 316) |
| Currently receiving ART, N (%) | 8 (44) | 7 (39) | 5 (28) |
| Antiretroviral therapy duration, median (range), weeks | 4 (0 – 62) | 3.7 (1.6 – 6.6) | 8.7 (0.7 – 196) |
| MRC TB meningitis grade, n (%) | |||
| I | 3 (15) | 1 (5) | 2 (9.5) |
| II | 13 (65) | 16 (80) | 12 (57.1) |
| III | 4 (20) | 3 (15) | 7 (33.3) |
| Uniform case definition, n (%) | |||
| Definite (microbiologically confirmed) | 8 (40) | 12 (60) | 11 (52.4) |
| Probable | 4 (20) | 4 (20) | 6 (28.6) |
| Possible | 7 (35) | 4 (20) | 1 (4.8) |
| Not | 1 (5) | 0 (0) | 3 (14.3) |
| CSF information, median (IQR) | |||
| Opening pressure, mmH20 | 230 (155–320) | 220 (135–300) | 135 (100–230) |
| White cells, cells/ µL) | 24 (4–162.5) | 4 (4–145) | 4 (4–122.5) |
| Protein, mg/dL | 154.5 (105–186) | 125 (73–188) | 92 (30–164) |
| Glucose, mg/dL | 41 (21–68) | 44 (21–66.7) | 38 (18–64) |
| Lactate, mmol/L | 8.5 (7.30–9.80) | 6.9 (2.9–11.1) | 8 (5.2–10.4) |
Abbreviations: ART, antiretroviral therapy; CSF, cerebrospinal fluid; HIV, human immunodeficiency virus; IQR, interquartile range; MRC, Medical Research Council; TB, tuberculosis.